• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB
Click for more information
1.67% 91.5¢

MESOBLAST LIMITED - Charts / Financials

Market Cap $1.044B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 25/04/2024 (20 minute delay) ?
Day
Open 92.0¢   Day High 93.5¢   Day Low 89.0¢
Daily Volume 7616298
Bids   Sellers
Number Price Volume   Number Price Volume
1 91.0¢ 6000   9 92.0¢ 134540

Directors & Senior Management

Dr. Silviu Itescu Chief Executive Officer, Executive Director
Mr. William M. Burns Non-Executive Independent Vice Chairman of the Board
Mr. Andrew Chaponnel Interim Chief Financial Officer
Ms. Dagmar Rosa-Bjorkeson Chief Operating Officer
Mr. Peter Howard General Counsel, Corporate Executive
Dr. Eric A. Rose Executive Director, Chief Medical Officer
Mr. Justin Horst Head of Manufacturing
Mr. Michael Schuster Pharma Partnering
Ms. Geraldine Storton Head of Regulatory Affairs and Quality Management
Mr. Paul Hughes Joint Company Secretary
Mrs. Jane Bell Non-Executive Independent Chairman of the Board
Mr. Philip J. Facchina Non-Executive Independent Director
Mr. Philip R. Krause Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
91.5¢ 		Change
0.015(1.67%) 		Mkt cap ! $1.044B
Open High Low Value Volume
92.0¢ 93.5¢ 89.0¢ $6.949M 7.616M

Buyers (Bids)

No. Vol. Price($)
1 6000 91.0¢
 

Sellers (Offers)

Price($) Vol. No.
92.0¢ 134540 9
View Market Depth
Last trade - 16.10pm 25/04/2024 (20 minute delay) ?
Last
90.5¢ 		  Change
0.015 ( 0.33 %)
Open High Low Volume
91.0¢ 93.5¢ 89.0¢ 1824946
Last updated 15.59pm 25/04/2024 ?

Top Stories

Recharged Prospects: 'Watts' on the horizon for copper & lithium

The conversation goes much deeper that this title suggests - it explores everything from projections on aluminium & manganese, to what a Donald Trump government could mean for commodities markets.
Aus inflation read of 3.6% spooks ASX – before quickly returning to green Australian inflation has come in mixed with an increase of 1% in the March quarter, but a decline from 4.1% in the December quarter.
High grade sniffs in Africa push Mako shares up 14% Mako Gold Ltd (ASX: MKG) has seen its shares jump above 14 percent on news that it has discovered a high grade zone with grades of 76 grams per tonne at its 868,000-ounce Napié Project in Côte d’Ivoire.Shares rose 14.28 percent to 16 cents on Wednesday, as the exploration company ...
Unith wraps up Q1 with $5M in cash as digital humans evolve Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But the bigger story is how good its digital humans are getting.
Lithium Universe eyes hydropower setup for greener battery metals Lithium Universe announced it has made an application in Canada for renewable electricity to power its lithium carbonate plant.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.